☆ 4.4 Article

Long-term Safety and Tolerability of Omadacycline for the Treatment of Mycobacterium abscessus Infections

OPEN FORUM INFECTIOUS DISEASES (2023)

Related references

Note: Only part of the references are listed.

Article Infectious Diseases

In vitro susceptibility patterns for rapidly growing nontuberculous mycobacteria in the United States

Joshua -J. Hunkins et al.

Summary: We developed a cumulative antibiogram for 14 rapidly growing mycobacteria (RGM) based on the largest sample size to date (N = 3860). All RGM showed high susceptibility to amikacin (82-100%). Mycobacterium abscessus had low susceptibility to most antimicrobials, but clofazimine exhibited low minimum inhibitory concentration (<= 0.5mg/L). Different sub-species showed variation in resistance mutations, with intact erm(41) detected in 70-100% of M. abscessus abscessus and bolletii. Mycobacterium chelonae exhibited similar susceptibility pattern to M. abscessus subsp. massiliense and M. immunogenum, but was susceptible to tobramycin (87%). Mycobacterium fortuitum complex and similar organisms showed higher susceptibility to fluoroquinolones, beta-lactams, linezolid, and trimethoprim/sulfamethoxazole. A comprehensive antibiogram can have a significant impact on treatment and monitoring of resistance patterns.

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2023)

Add to Collection

Article Microbiology

Potency of Omadacycline against Mycobacteroides abscessus Clinical Isolates In Vitro and in a Mouse Model of Pulmonary Infection

Danielle A. Nicklas et al.

Summary: The incidence of nontuberculous mycobacterial diseases in the United States is rising and has surpassed that of tuberculosis. Mycobacteroides abscessus is an important pathogen capable of causing chronic infections and is difficult to treat. The study found that omadacycline, a new tetracycline derivative, showed activity against M. abscessus and exhibited synergism with several commonly used antibiotics.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)

Add to Collection

Article Critical Care Medicine

Treatment of Mycobacterium abscessus Pulmonary Disease

David E. Griffith et al.

Summary: Mycobacterium abscessus, a common pathogen in nontuberculous mycobacterial lung diseases, has different subspecies with varying drug susceptibilities. Macrolides and amikacin are commonly used drugs, but their efficacy is limited against resistant strains. New drugs show promising in vitro activity, but further validation is needed.

CHEST (2022)

Add to Collection

Article Microbiology

Challenges and a potential solution to perform drug susceptibility testing of omadacycline against nontuberculous mycobacteria

Prem Shankar et al.

TUBERCULOSIS (2022)

Add to Collection

Article Infectious Diseases

Omadacycline in first-line combination therapy for pulmonary Mycobacterium abscessus infection: a case series

Marylene Duah et al.

Summary: Mycobacterium abscessus complex (MABSC) is a common cause of nontuberculous mycobacterial pulmonary disease, but there are currently no approved treatments. This study reports on three cases where omadacycline was used as part of a first-line treatment for patients with MABSC pulmonary infections, showing promising clinical improvements and supporting further investigation of omadacycline as a potential treatment option.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2022)

Add to Collection

Article Microbiology

In Vitro Susceptibility Testing of Omadacycline against Nontuberculous Mycobacteria

Barbara A. Brown-Elliott et al.

Summary: This study evaluated the in vitro potency of the new tetracycline derivative omadacycline against NTM, showing high activity against most RGM species. MIC testing against RGM revealed over 90% resistance to tetracycline in the isolates tested.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)

Add to Collection

Article Immunology

Preliminary, Real-world, Multicenter Experience With Omadacycline for Mycobacterium abscessus Infections

Taylor Morrisette et al.

Summary: In this study, 12 patients with Mycobacterium abscessus infection were treated with omadacycline as part of a multidrug regimen. The median duration of OMC treatment was relatively long, and overall clinical success was observed in 75% of patients, with three patients experiencing possible adverse effects.

OPEN FORUM INFECTIOUS DISEASES (2021)

Add to Collection

Article Immunology

Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline: Executive Summary

Charles L. Daley et al.

CLINICAL INFECTIOUS DISEASES (2020)

Add to Collection

Article Immunology

Omadacycline for the Treatment of Mycobacterium abscessus Disease: A Case Series

Jeffrey C. Pearson et al.

OPEN FORUM INFECTIOUS DISEASES (2020)

Add to Collection

Article Microbiology

In Vitro Activities of Omadacycline against Rapidly Growing Mycobacteria

Carolyn Shoen et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)

Add to Collection

Article Medicine, General & Internal

Omadacycline for Acute Bacterial Skin and Skin-Structure Infections

William O'Riordan et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Medicine, General & Internal

Omadacycline for Community-Acquired Bacterial Pneumonia

Roman Stets et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Microbiology

In Vitro Activity of New Tetracycline Analogs Omadacycline and Eravacycline against Drug-Resistant Clinical Isolates of Mycobacterium abscessus

Amit Kaushik et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)

Add to Collection

Article Immunology

An Integrated Safety Summary of Omadacycline, a Novel Aminomethylcycline Antibiotic

Steven Opal et al.

CLINICAL INFECTIOUS DISEASES (2019)

Add to Collection

Article Infectious Diseases

Omadacycline as a promising new agent for the treatment of infections with Mycobacterium abscessus

Hannelore I. Bax et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)

Add to Collection

Article Computer Science, Interdisciplinary Applications

The REDCap consortium: Building an international community of software platform partners

Paul A. Harris et al.

JOURNAL OF BIOMEDICAL INFORMATICS (2019)

Add to Collection

Article Infectious Diseases

Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial

William O'Riordan et al.

LANCET INFECTIOUS DISEASES (2019)

Add to Collection

Article Microbiology

Tigecycline Is Highly Efficacious against Mycobacterium abscessus Pulmonary Disease

Beatriz E. Ferro et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)

Add to Collection

Article Infectious Diseases

Advances in the management of pulmonary disease due to Mycobacterium abscessus complex

W-J. Koh et al.

INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2014)

Add to Collection

Article Computer Science, Interdisciplinary Applications

Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support

Paul A. Harris et al.

JOURNAL OF BIOMEDICAL INFORMATICS (2009)

Add to Collection

Article Microbiology

Cohort Study of Molecular Identification and Typing of Mycobacterium abscessus, Mycobacterium massiliense, and Mycobacterium bolletii

Adrian M. Zelazny et al.

JOURNAL OF CLINICAL MICROBIOLOGY (2009)

Add to Collection

© Peeref 2019-2024. All rights reserved.